Bank of America (BofA) identified key life sciences and biotech stocks poised for outperformance in 2026. The firm emphasized companies such as Thermo Fisher Scientific, IQVIA Holdings, Guardant Health, and Elanco Animal Health for their innovation, strong market positioning, and favorable growth outlook. These leaders are set to capitalize on sector momentum driven by diagnostic advances, clinical analytics, and animal health developments.

Thermo Fisher and IQVIA Lead Sector Growth

Thermo Fisher Scientific (TMO) remains BofA’s top pick in the Life Sciences Tools sector, with the bank raising its price target to $700 while reaffirming a Buy rating. The company forecasts fiscal 2026 revenue growth between 3% and 4%, alongside operating margin expansion exceeding 50 basis points, excluding an estimated 45-cent accretion from its Clario acquisition in year one. Thermo Fisher is positioned to benefit from reshoring trends and improving demand across academia, government, and pharmaceutical sectors. Recent analyst endorsements include upgrades from KeyBanc, Morgan Stanley, and Goldman Sachs. The firm also announced plans to expand bioprocessing capabilities in Asia to support rising biopharma activity.

IQVIA Holdings (IQV) enters 2026 with a de-risked outlook. Management projects approximately 5% reported revenue growth for the year, driving BofA to increase its price objective to $260 and maintain a Buy rating. The company benefits from shortened client decision cycles and steadier request-for-proposal flows, which enhance revenue predictability amid sector variability. IQVIA’s Technology & Analytics Solutions segment, underpinned by growing AI adoption, remains a key growth engine. Notably, the firm recently partnered with Amazon Web Services to boost its AI platform for clinical trials. Stifel and Morgan Stanley have also issued positive analyst coverage.

Guardant Health and Elanco Animal Health Set for Expansion

Guardant Health (GH) is expected to capture growth opportunities from molecular diagnostic and liquid biopsy markets. With products like G360 Liquid still early in adoption, the company’s broad cancer care portfolio offers substantial upside. BofA reaffirmed its Buy rating and increased the price target to $120, citing catalysts such as upcoming FDA approval prospects for G360 Liquid and expansion of its Reveal blood test in breast cancer therapy monitoring. Jefferies and BTIG have also boosted their outlooks, highlighting Guardant as a top pick for 2026.

In Animal Health, Elanco Animal Health (ELAN) stands out as BofA’s preferred stock. Despite headwinds from reduced veterinary visits and consumer pressures, Elanco’s product pipeline, including new launches like Credelio Quattro and Zenrelia, supports sustained growth. The company’s Befrena development and relatively lower exposure to clinic traffic help it weather challenging market conditions. The FDA’s conditional approval of Credelio Quattro-CA1 for treating New World screwworm larvae in dogs further strengthens its growth prospects. Analysts from Leerink Partners, Stifel, and KeyBanc continue to maintain favorable ratings.

Biotech Market Outlook for 2026

The biotech and life sciences sectors are set for significant advancements in 2026, driven by innovation in diagnostics, AI-driven analytics, and animal health solutions. Bank of America’s comprehensive analysis underscores companies with strong fundamentals and strategic initiatives that align with reshoring trends and advancing technologies. Investors interested in biotech exposure should monitor these frontrunners, as evolving market dynamics and product expansions are projected to fuel sustained sector growth and appealing investment opportunities.